A citation-based method for searching scientific literature

Johnny Ludvigsson, Maria Faresjö, Maria Hjorth, Stina Axelsson, Mikael Chéramy, Mikael Pihl, Outi Vaarala, Gun Forsander, Sten Ivarsson, Calle Johansson, Agne Lindh, Nils-Osten Nilsson, Jan Aman, Eva Ortqvist, Peter Zerhouni, Rosaura Casas. N Engl J Med 2008
Times Cited: 332







List of co-cited articles
1012 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


GAD65 antigen therapy in recently diagnosed type 1 diabetes mellitus.
Johnny Ludvigsson, David Krisky, Rosaura Casas, Tadej Battelino, Luis Castaño, James Greening, Olga Kordonouri, Timo Otonkoski, Paolo Pozzilli, Jean-Jacques Robert,[...]. N Engl J Med 2012
188
53

Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Diane K Wherrett, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks,[...]. Lancet 2011
226
51

Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Mark D Pescovitz, Carla J Greenbaum, Heidi Krause-Steinrauf, Dorothy J Becker, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Jennifer B Marks, Paula F McGee, Antoinette M Moran,[...]. N Engl J Med 2009
628
40

Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes.
Bart Keymeulen, Evy Vandemeulebroucke, Anette G Ziegler, Chantal Mathieu, Leonard Kaufman, Geoff Hale, Frans Gorus, Michel Goldman, Markus Walter, Sophie Candon,[...]. N Engl J Med 2005
784
37

Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial.
Nicole Sherry, William Hagopian, Johnny Ludvigsson, Sunil M Jain, Jack Wahlen, Robert J Ferry, Bruce Bode, Stephen Aronoff, Christopher Holland, David Carlin,[...]. Lancet 2011
290
34

Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trial.
Tihamer Orban, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Peter A Gottlieb, Carla J Greenbaum, Jennifer B Marks, Roshanak Monzavi,[...]. Lancet 2011
347
32

Effects of oral insulin in relatives of patients with type 1 diabetes: The Diabetes Prevention Trial--Type 1.
Jay S Skyler, Jeffrey P Krischer, Joseph Wolfsdorf, Catherine Cowie, Jerry P Palmer, Carla Greenbaum, David Cuthbertson, Lisa E Rafkin-Mervis, H Peter Chase, Ellen Leschek. Diabetes Care 2005
384
32

Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial.
Kirsti Näntö-Salonen, Antti Kupila, Satu Simell, Heli Siljander, Tiina Salonsaari, Anne Hekkala, Sari Korhonen, Risto Erkkola, Jukka I Sipilä, Lotta Haavisto,[...]. Lancet 2008
241
30

Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus.
Kevan C Herold, William Hagopian, Julie A Auger, Ena Poumian-Ruiz, Lesley Taylor, David Donaldson, Stephen E Gitelman, David M Harlan, Danlin Xu, Robert A Zivin,[...]. N Engl J Med 2002
835
30


Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials.
Antoinette Moran, Brian Bundy, Dorothy J Becker, Linda A DiMeglio, Stephen E Gitelman, Robin Goland, Carla J Greenbaum, Kevan C Herold, Jennifer B Marks, Philip Raskin,[...]. Lancet 2013
206
24

A single course of anti-CD3 monoclonal antibody hOKT3gamma1(Ala-Ala) results in improvement in C-peptide responses and clinical parameters for at least 2 years after onset of type 1 diabetes.
Kevan C Herold, Stephen E Gitelman, Umesh Masharani, William Hagopian, Brygida Bisikirska, David Donaldson, Kristina Rother, Beverly Diamond, David M Harlan, Jeffrey A Bluestone. Diabetes 2005
456
21

Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial.
William Hagopian, Robert J Ferry, Nicole Sherry, David Carlin, Ezio Bonvini, Syd Johnson, Kathryn E Stein, Scott Koenig, Anastasia G Daifotis, Kevan C Herold,[...]. Diabetes 2013
115
19

C-peptide levels and insulin independence following autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Carlos E B Couri, Maria C B Oliveira, Ana B P L Stracieri, Daniela A Moraes, Fabiano Pieroni, George M N Barros, Maria Isabel A Madeira, Kelen C R Malmegrim, Maria C Foss-Freitas, Belinda P Simões,[...]. JAMA 2009
266
18

Pancreatic beta-cell function and immune responses to insulin after administration of intranasal insulin to humans at risk for type 1 diabetes.
Leonard C Harrison, Margo C Honeyman, Cheryl E Steele, Natalie L Stone, Elena Sarugeri, Ezio Bonifacio, Jennifer J Couper, Peter G Colman. Diabetes Care 2004
130
17

Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs β-cell function.
S Alice Long, Mary Rieck, Srinath Sanda, Jennifer B Bollyky, Peter L Samuels, Robin Goland, Andrew Ahmann, Alex Rabinovitch, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2012
209
17

Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Kevan C Herold, Stephen E Gitelman, Mario R Ehlers, Peter A Gottlieb, Carla J Greenbaum, William Hagopian, Karen D Boyle, Lynette Keyes-Elstein, Sudeepta Aggarwal, Deborah Phippard,[...]. Diabetes 2013
183
17

Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes.
Michael J Haller, Stephen E Gitelman, Peter A Gottlieb, Aaron W Michels, Stephen M Rosenthal, Jonathan J Shuster, Baiming Zou, Todd M Brusko, Maigan A Hulme, Clive H Wasserfall,[...]. J Clin Invest 2015
93
18

Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass.
B Keymeulen, M Walter, C Mathieu, L Kaufman, F Gorus, R Hilbrands, E Vandemeulebroucke, U Van de Velde, L Crenier, C De Block,[...]. Diabetologia 2010
211
16

Clinical evidence for the safety of GAD65 immunomodulation in adult-onset autoimmune diabetes.
Carl-David Agardh, Corrado M Cilio, AsaLinda Lethagen, Kristian Lynch, R David G Leslie, Mats Palmér, Robert A Harris, John A Robertson, Ake Lernmark. J Diabetes Complications 2005
149
16

Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus.
Júlio C Voltarelli, Carlos E B Couri, Ana B P L Stracieri, Maria C Oliveira, Daniela A Moraes, Fabiano Pieroni, Marina Coutinho, Kelen C R Malmegrim, Maria C Foss-Freitas, Belinda P Simões,[...]. JAMA 2007
353
16

Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children.
Anette G Ziegler, Marian Rewers, Olli Simell, Tuula Simell, Johanna Lempainen, Andrea Steck, Christiane Winkler, Jorma Ilonen, Riitta Veijola, Mikael Knip,[...]. JAMA 2013
523
16

Oral insulin administration and residual beta-cell function in recent-onset type 1 diabetes: a multicentre randomised controlled trial. Diabète Insuline Orale group.
L Chaillous, H Lefèvre, C Thivolet, C Boitard, N Lahlou, C Atlan-Gepner, B Bouhanick, A Mogenet, M Nicolino, J C Carel,[...]. Lancet 2000
176
15


Extended evaluation of the safety and efficacy of GAD treatment of children and adolescents with recent-onset type 1 diabetes: a randomised controlled trial.
J Ludvigsson, M Hjorth, M Chéramy, S Axelsson, M Pihl, G Forsander, N-Ö Nilsson, B-O Samuelsson, T Wood, J Aman,[...]. Diabetologia 2011
44
34


Beta-cell function and the development of diabetes-related complications in the diabetes control and complications trial.
Michael W Steffes, Shalamar Sibley, Melissa Jackson, William Thomas. Diabetes Care 2003
449
15

Etanercept treatment in children with new-onset type 1 diabetes: pilot randomized, placebo-controlled, double-blind study.
Lucy Mastrandrea, Jihnhee Yu, Torsten Behrens, John Buchlis, Christine Albini, Shannon Fourtner, Teresa Quattrin. Diabetes Care 2009
142
15

Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study.
S L Thrower, L James, W Hall, K M Green, S Arif, J S Allen, C Van-Krinks, B Lozanoska-Ochser, L Marquesini, S Brown,[...]. Clin Exp Immunol 2009
104
15

GAD-treatment of children and adolescents with recent-onset type 1 diabetes preserves residual insulin secretion after 30 months.
Johnny Ludvigsson, Mikael Chéramy, Stina Axelsson, Mikael Pihl, Linda Akerman, Rosaura Casas. Diabetes Metab Res Rev 2014
25
60

No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes.
Markus Walter, Areti Philotheou, François Bonnici, Anette-G Ziegler, Roland Jimenez. Diabetes Care 2009
78
19


Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
Mark R Rigby, Kristina M Harris, Ashley Pinckney, Linda A DiMeglio, Marc S Rendell, Eric I Felner, Jean M Dostou, Stephen E Gitelman, Kurt J Griffin, Eva Tsalikian,[...]. J Clin Invest 2015
137
14

No effect of oral insulin on residual beta-cell function in recent-onset type I diabetes (the IMDIAB VII). IMDIAB Group.
P Pozzilli, D Pitocco, N Visalli, M G Cavallo, R Buzzetti, A Crinò, S Spera, C Suraci, G Multari, M Cervoni,[...]. Diabetologia 2000
146
13

Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8⁺ T cells in type 1 diabetes.
Bart O Roep, Nanette Solvason, Peter A Gottlieb, Joana R F Abreu, Leonard C Harrison, George S Eisenbarth, Liping Yu, Michael Leviten, William A Hagopian, John B Buse,[...]. Sci Transl Med 2013
96
13

Type 1 diabetes.
Mark A Atkinson, George S Eisenbarth, Aaron W Michels. Lancet 2014
987
13

Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial.
Ezio Bonifacio, Anette-G Ziegler, Georgeanna Klingensmith, Edith Schober, Polly J Bingley, Marietta Rottenkolber, Anke Theil, Anne Eugster, Ramona Puff, Claudia Peplow,[...]. JAMA 2015
96
13

Type 1 diabetes immunotherapy using polyclonal regulatory T cells.
Jeffrey A Bluestone, Jane H Buckner, Mark Fitch, Stephen E Gitelman, Shipra Gupta, Marc K Hellerstein, Kevan C Herold, Angela Lares, Michael R Lee, Kelvin Li,[...]. Sci Transl Med 2015
471
13

Analysis of islet inflammation in human type 1 diabetes.
A Willcox, S J Richardson, A J Bone, A K Foulis, N G Morgan. Clin Exp Immunol 2009
406
12

GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
Maria Hjorth, Stina Axelsson, Anna Rydén, Maria Faresjö, Johnny Ludvigsson, Rosaura Casas. Clin Immunol 2011
47
25

Effect of heat shock protein peptide DiaPep277 on beta-cell function in paediatric and adult patients with recent-onset diabetes mellitus type 1: two prospective, randomized, double-blind phase II trials.
Nanette C Schloot, Guido Meierhoff, Csaba Lengyel, Gyözö Vándorfi, József Takács, Pál Pánczél, László Barkai, László Madácsy, Tamás Oroszlán, Peter Kovács,[...]. Diabetes Metab Res Rev 2007
78
15

Heat-shock protein peptide DiaPep277 treatment in children with newly diagnosed type 1 diabetes: a randomised, double-blind phase II study.
L Lazar, R Ofan, N Weintrob, A Avron, M Tamir, D Elias, M Phillip, Z Josefsberg. Diabetes Metab Res Rev 2007
73
16


Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized, comparative trial.
Jay S Skyler, Ruth S Weinstock, Philip Raskin, Jean-François Yale, Eugene Barrett, John E Gerich, Hertzel C Gerstein. Diabetes Care 2005
234
12

Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
Carla J Greenbaum, Craig A Beam, David Boulware, Stephen E Gitelman, Peter A Gottlieb, Kevan C Herold, John M Lachin, Paula McGee, Jerry P Palmer, Mark D Pescovitz,[...]. Diabetes 2012
190
12

Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice.
J Tian, M Clare-Salzler, A Herschenfeld, B Middleton, D Newman, R Mueller, S Arita, C Evans, M A Atkinson, Y Mullen,[...]. Nat Med 1996
223
12

Cellular and humoral immune responses in type 1 diabetic patients participating in a phase III GAD-alum intervention trial.
Stina Axelsson, Mikael Chéramy, Linda Akerman, Mikael Pihl, Johnny Ludvigsson, Rosaura Casas. Diabetes Care 2013
19
63

IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells.
Yenkel Grinberg-Bleyer, Audrey Baeyens, Sylvaine You, Rima Elhage, Gwladys Fourcade, Sylvie Gregoire, Nicolas Cagnard, Wassila Carpentier, Qizhi Tang, Jeffrey Bluestone,[...]. J Exp Med 2010
275
11

Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
Stina Axelsson, Mikael Chéramy, Maria Hjorth, Mikael Pihl, Linda Akerman, Emanuela Martinuzzi, Roberto Mallone, Johnny Ludvigsson, Rosaura Casas. PLoS One 2011
31
35



Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.